Skip to content
Evigrade
MajorAntiretroviral, HIV protease inhibitor×Triptan, selective 5HT1B/1D receptor agonist

Updated · Methodology

Mechanism

The liver breaks down eletriptan mainly through the enzyme CYP3A4, and atazanavir inhibits this enzyme. The standard atazanavir regimen includes a booster (ritonavir or cobicistat). Both boosters strongly inhibit CYP3A, and ritonavir inhibits it more strongly than atazanavir itself. The labels give no study of this exact pair, so the closest guide is data on other strong inhibitors. Ketoconazole 400 mg raised the eletriptan area under the curve (AUC) 5.9-fold and lengthened its half-life from 4.8 to 8.3 hours. Erythromycin 1000 mg raised the AUC 3.6-fold. Because of this rise in exposure, the labels do not allow eletriptan with strong CYP3A4 inhibitors. Like other triptans, eletriptan narrows blood vessels and can cause coronary artery spasm.

Symptoms

Tightness, pain or pressure in the chest, throat, neck and jaw is common after eletriptan. It is usually not cardiac but can be a sign of coronary artery spasm. Myocardial infarction, ventricular tachycardia and ventricular fibrillation have occurred within a few hours of triptan use, sometimes in people without known heart disease. Rarely, blood pressure rises sharply, even to a hypertensive crisis. Spasm of other arteries can cause Raynaud's syndrome or bowel ischaemia with abdominal pain and bloody diarrhoea. Stroke and brain haemorrhage have occurred after triptans.

Management

The atazanavir summary of product characteristics (SmPC) pairs atazanavir with a booster (ritonavir or cobicistat) and allows it without a booster only under restricted conditions (European Medicines Agency, EMA). The eletriptan SmPC says not to use eletriptan with strong inhibitors of the enzyme CYP3A4 and names ritonavir among them (Spanish Agency of Medicines and Medical Devices, AEMPS). With ritonavir as the booster, the combination is contraindicated (eletriptan label, US Food and Drug Administration, FDA). The label bans eletriptan within at least 72 hours of ritonavir and sets no dose condition, so the ban also covers the low ritonavir dose used with atazanavir. With cobicistat, including the atazanavir and cobicistat tablet, do not give eletriptan during treatment or for at least 72 hours after the last dose (eletriptan label, FDA). Cobicistat is also a strong CYP3A inhibitor (Evotaz SmPC, EMA). Unboosted atazanavir also inhibits CYP3A, but more weakly than ritonavir (atazanavir SmPC, EMA, and label, FDA). There are no data on this pair for that regimen. If eletriptan has been taken and chest pain or tightness suggesting cardiac ischaemia appears, give no further doses and evaluate the heart (eletriptan SmPC, AEMPS). Stop eletriptan if arrhythmias occur and monitor blood pressure during treatment (eletriptan label, FDA). If signs of spasm in other arteries appear, such as abdominal pain with blood in the stool or white, cold fingers, rule out vasospasm before the next dose (eletriptan label, FDA).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Atazanavir

Other interactions with Eletriptan